BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25442349)

  • 1. Modelling the impact of fractionation on late urinary toxicity after postprostatectomy radiation therapy.
    Fiorino C; Cozzarini C; Rancati T; Briganti A; Cattaneo GM; Mangili P; Di Muzio NG; Calandrino R
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1250-7. PubMed ID: 25442349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
    Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N
    Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients.
    Cozzarini C; Fiorino C; Da Pozzo LF; Alongi F; Berardi G; Bolognesi A; Briganti A; Broggi S; Deli A; Guazzoni G; Perna L; Pasetti M; Salvadori G; Montorsi F; Rigatti P; Di Muzio N
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):191-9. PubMed ID: 21109361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancer.
    Defraene G; Van den Bergh L; Al-Mamgani A; Haustermans K; Heemsbergen W; Van den Heuvel F; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1233-42. PubMed ID: 21664059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer.
    Alongi F; Cozzi L; Fogliata A; Iftode C; Comito T; Clivio A; Villa E; Lobefalo F; Navarria P; Reggiori G; Mancosu P; Clerici E; Tomatis S; Taverna G; Graziotti P; Scorsetti M
    Anticancer Res; 2013 Oct; 33(10):4537-43. PubMed ID: 24123027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematologic Toxicity in Patients Treated With Postprostatectomy Whole-Pelvis Irradiation With Different Intensity Modulated Radiation Therapy Techniques Is Not Negligible and Is Prolonged: Preliminary Results of a Longitudinal, Observational Study.
    Cozzarini C; Noris Chiorda B; Sini C; Fiorino C; Briganti A; Montorsi F; Di Muzio N
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):690-5. PubMed ID: 27131081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
    Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation pneumonitis after hypofractionated radiotherapy: evaluation of the LQ(L) model and different dose parameters.
    Borst GR; Ishikawa M; Nijkamp J; Hauptmann M; Shirato H; Bengua G; Onimaru R; de Josien Bois A; Lebesque JV; Sonke JJ
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1596-603. PubMed ID: 20231066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction.
    Wennberg BM; Baumann P; Gagliardi G; Nyman J; Drugge N; Hoyer M; Traberg A; Nilsson K; Morhed E; Ekberg L; Wittgren L; Lund JÅ; Levin N; Sederholm C; Lewensohn R; Lax I
    Acta Oncol; 2011 May; 50(4):518-27. PubMed ID: 21198416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modern hypofractionation schedules for tangential whole breast irradiation decrease the fraction size-corrected dose to the heart.
    Appelt AL; Vogelius IR; Bentzen SM
    Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):147-52. PubMed ID: 22910644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA; Kestin LL; Martinez AA
    Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial.
    Katayama S; Striecker T; Kessel K; Sterzing F; Habl G; Edler L; Debus J; Herfarth K
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):926-33. PubMed ID: 25216858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer.
    Cheng JC; Schultheiss TE; Nguyen KH; Wong JY
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):351-7. PubMed ID: 18164841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Fraction Size Sensitivity of Late Genitourinary Toxicity: Analysis of Alpha/Beta (α/β) Ratios in the CHHiP Trial.
    Brand DH; Brüningk SC; Wilkins A; Naismith O; Gao A; Syndikus I; Dearnaley DP; van As N; Hall E; Gulliford S; Tree AC;
    Int J Radiat Oncol Biol Phys; 2023 Feb; 115(2):327-336. PubMed ID: 35985457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofractionation: what does it mean for prostate cancer treatment?
    Liao Y; Joiner M; Huang Y; Burmeister J
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):260-8. PubMed ID: 19879698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical comparison of two linear-quadratic model-based isoeffect fractionation schemes of high-dose-rate intracavitary brachytherapy for cervical cancer.
    Wang CJ; Huang EY; Sun LM; Chen HC; Fang FM; Hsu HC; Changchien CC; Leung SW
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):179-89. PubMed ID: 15093915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity analysis of parameters in linear-quadratic radiobiologic modeling.
    Fowler JF
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1532-7. PubMed ID: 19306749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial.
    Brand DH; Brüningk SC; Wilkins A; Fernandez K; Naismith O; Gao A; Syndikus I; Dearnaley DP; Tree AC; van As N; Hall E; Gulliford S;
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):596-608. PubMed ID: 33412260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.